Sergeeva M - Search Results

1

SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19.

Stanevich OV, Alekseeva EI, Sergeeva M, Fadeev AV, Komissarova KS, Ivanova AA, Simakova TS, Vasilyev KA, Shurygina AP, Stukova MA, Safina KR, Nabieva ER, Garushyants SK, Klink GV, Bakin EA, Zabutova JV, Kholodnaia AN, Lukina OV, Skorokhod IA, Ryabchikova VV, Medvedeva NV, Lioznov DA, Danilenko DM, Chudakov DM, Komissarov AB, Bazykin GA. Stanevich OV, et al. Among authors: sergeeva m. Nat Commun. 2023 Jan 10;14(1):149. doi: 10.1038/s41467-022-34033-x. Nat Commun. 2023. PMID: 36627290 Free PMC article.

2

Rapid spread of influenza A(H1N1)pdm09 viruses with a new set of specific mutations in the internal genes in the beginning of 2015/2016 epidemic season in Moscow and Saint Petersburg (Russian Federation).

Komissarov A, Fadeev A, Sergeeva M, Petrov S, Sintsova K, Egorova A, Pisareva M, Buzitskaya Z, Musaeva T, Danilenko D, Konovalova N, Petrova P, Stolyarov K, Smorodintseva E, Burtseva E, Krasnoslobodtsev K, Kirillova E, Karpova L, Eropkin M, Sominina A, Grudinin M. Komissarov A, et al. Among authors: sergeeva m. Influenza Other Respir Viruses. 2016 Jul;10(4):247-53. doi: 10.1111/irv.12389. Epub 2016 May 27. Influenza Other Respir Viruses. 2016. PMID: 26992820 Free PMC article.

3

[Impact of mutations in nucleoprotein on replication of influenza virus A/Hong Kong/1/68/162/35 reassortants at different temperatures].

Pulkina AA, Sergeeva MV, Petrov SV, Fadeev AV, Komissarov AB, Romanovskaya-Romanko EA, Potapchuk MV, Tsybalova LM. Pulkina AA, et al. Among authors: sergeeva mv. Mol Biol (Mosk). 2017 Mar-Apr;51(2):378-383. doi: 10.7868/S0026898417010141. Mol Biol (Mosk). 2017. PMID: 28537245 Free article. Russian.

4

Intranasal Immunization with the Influenza A Virus Encoding Truncated NS1 Protein Protects Mice from Heterologous Challenge by Restraining the Inflammatory Response in the Lungs.

Vasilyev K, Shurygina AP, Sergeeva M, Stukova M, Egorov A. Vasilyev K, et al. Among authors: sergeeva m. Microorganisms. 2021 Mar 26;9(4):690. doi: 10.3390/microorganisms9040690. Microorganisms. 2021. PMID: 33810549 Free PMC article.

5

Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan.

Zakarya K, Kutumbetov L, Orynbayev M, Abduraimov Y, Sultankulova K, Kassenov M, Sarsenbayeva G, Kulmagambetov I, Davlyatshin T, Sergeeva M, Stukova M, Khairullin B. Zakarya K, et al. Among authors: sergeeva m. EClinicalMedicine. 2021 Sep;39:101078. doi: 10.1016/j.eclinm.2021.101078. Epub 2021 Aug 14. EClinicalMedicine. 2021. PMID: 34414368 Free PMC article.

6

Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization.

Karyagina AS, Gromov AV, Grunina TM, Lyaschuk AM, Poponova MS, Kleymenov DA, Strukova NV, Generalova MS, Ryazanova AV, Galushkina ZM, Dobrynina OY, Bolshakova TN, Sergeeva MV, Romanovskaya-Romanko EA, Krasilnikov IV, Subbotina ME, Lunin VG. Karyagina AS, et al. Among authors: sergeeva mv. Biochemistry (Mosc). 2022 Apr;87(4):319-330. doi: 10.1134/S0006297922040022. Biochemistry (Mosc). 2022. PMID: 35527370 Free PMC article.

7

VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages.

Kulemzin SV, Sergeeva MV, Baranov KO, Gorchakov AA, Guselnikov SV, Belovezhets TN, Volkova OY, Najakshin AM, Chikaev NA, Danilenko DM, Taranin AV. Kulemzin SV, et al. Among authors: sergeeva mv. J Pers Med. 2022 May 29;12(6):895. doi: 10.3390/jpm12060895. J Pers Med. 2022. PMID: 35743680 Free PMC article.

8

Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine.

Kordyukova LV, Moiseenko AV, Serebryakova MV, Shuklina MA, Sergeeva MV, Lioznov DA, Shanko AV. Kordyukova LV, et al. Viruses. 2023 Feb 9;15(2):480. doi: 10.3390/v15020480. Viruses. 2023. PMID: 36851694 Free PMC article.

9

An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.

Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, Kiselev OI, Stukova MA. Sansyzbay AR, et al. Among authors: sergeeva mv. Clin Vaccine Immunol. 2013 Aug;20(8):1314-9. doi: 10.1128/CVI.00096-13. Epub 2013 Jun 26. Clin Vaccine Immunol. 2013. PMID: 23803900 Free PMC article. Clinical Trial.

10

Cold and distant: structural features of the nucleoprotein complex of a cold-adapted influenza A virus strain.

Shvetsov AV, Lebedev DV, Zabrodskaya YA, Shaldzhyan AA, Egorova MA, Vinogradova DS, Konevega AL, Gorshkov AN, Ramsay ES, Radulescu A, Sergeeva MV, Plotnikova MA, Komissarov AB, Taraskin AS, Lebedev KI, Garmay YP, Kuznetsov VV, Isaev-Ivanov VV, Vasin AV, Tsybalova LM, Egorov VV. Shvetsov AV, et al. Among authors: sergeeva mv. J Biomol Struct Dyn. 2021 Aug;39(12):4375-4384. doi: 10.1080/07391102.2020.1776636. Epub 2020 Jun 16. J Biomol Struct Dyn. 2021. PMID: 32490728

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

214 results

Search Page

Filters